成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

美國(guó)VaxInnate
VaxInnate公司是一家私人持有的生物技術(shù)公司，開發(fā)新穎，專有疫苗為大流行病和季節(jié)性流感。該公司的突破疫苗是基于其Toll樣受體（ TLR為）的技術(shù)平臺(tái)，大大提高了疫苗的免疫原性和有效性。利用TLR為技術(shù)，疫苗可產(chǎn)生的簡(jiǎn)單，低成本，高可擴(kuò)展性重組DNA技術(shù)，避免許多挑戰(zhàn)和隱患的雞蛋或細(xì)胞培養(yǎng)流感疫苗的生產(chǎn)。 VaxInnate的技術(shù)有可能顯著提高成本效益，制造能力和效力的流感疫苗-面臨的關(guān)鍵問題的臨床和公共健康的社區(qū)。

美國(guó)生物制藥公司VaxInnate總裁艾倫·肖在接受新華社記者采訪時(shí)表示，針對(duì)這種新型病毒(豬流感病毒)的疫苗樣品有望在4周內(nèi)研制成功。

VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy. Using the TLR technology, vaccines can be produced by simple, low-cost, highly-scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate's technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines - key issues facing the clinical and public health communities.

VaxInnate has a BSL2+ laboratory operational within the Cranbury site, and also has access to BSL-2 vivarium space through a collaborative research agreement with Yale University . VaxInnate also has a collaborative arrangement with an academic institution for access to high level biocontainment facilities (BSL-3 and -4). Since avian influenza requires BSL-3 or -4 facilities, depending on the strain in question, this access enables the VaxInnate to conduct live virus challenges in animal models.

VaxInnate was founded by Ruslan Medzhitov and Richard Flavell, both of Yale University and Howard Hughes Medical Institute and leaders in the field of innate immunity. The company started in 2002 with Michael Sherman serving as Chief Executive Officer and a research team in New Haven , CT. In 2004, the company expanded and established a development team and corporate headquarters in Cranbury , NJ . The company currently has approximately 58 employees including 18 with doctoral degrees.

Currently, VaxInnate occupies approximately 30,000 square feet of laboratory and office space in Cranbury , NJ , and New Haven , CT. This includes molecular and cell biology labs, cell culture facilities, a protein pilot plant and analytical laboratory space.

VaxInnate has raised more than $64 million to date and is backed by well-known venture capital firms, including HealthCare Ventures, Oxford Bioscience Partners LLC, MedImmune Ventures, Inc., CHL Medical Partners, New Leaf Venture Partners, and Canaan Partners.